Free Trial
NASDAQ:EPIX

ESSA Pharma (EPIX) Stock Price, News & Analysis

ESSA Pharma logo
$1.91 0.00 (0.00%)
Closing price 08/19/2025 04:00 PM Eastern
Extended Trading
$1.92 +0.01 (+0.26%)
As of 04:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About ESSA Pharma Stock (NASDAQ:EPIX)

Key Stats

Today's Range
$1.91
$1.92
50-Day Range
$1.67
$1.93
52-Week Range
$1.40
$7.88
Volume
241,767 shs
Average Volume
320,098 shs
Market Capitalization
$90.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.00
Consensus Rating
Hold

Company Overview

ESSA Pharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
32nd Percentile Overall Score

EPIX MarketRank™: 

ESSA Pharma scored higher than 32% of companies evaluated by MarketBeat, and ranked 800th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    ESSA Pharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    ESSA Pharma has received no research coverage in the past 90 days.

  • Read more about ESSA Pharma's stock forecast and price target.
  • Earnings Growth

    Earnings for ESSA Pharma are expected to grow in the coming year, from ($0.42) to ($0.17) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of ESSA Pharma is -3.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of ESSA Pharma is -3.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    ESSA Pharma has a P/B Ratio of 0.83. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    2.05% of the float of ESSA Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    ESSA Pharma has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in ESSA Pharma has recently increased by 12.35%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    ESSA Pharma does not currently pay a dividend.

  • Dividend Growth

    ESSA Pharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.05% of the float of ESSA Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    ESSA Pharma has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in ESSA Pharma has recently increased by 12.35%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    ESSA Pharma has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for ESSA Pharma this week, compared to 6 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, ESSA Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $293.00 in company stock.

  • Percentage Held by Insiders

    15.50% of the stock of ESSA Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    75.12% of the stock of ESSA Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about ESSA Pharma's insider trading history.
Receive EPIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ESSA Pharma and its competitors with MarketBeat's FREE daily newsletter.

EPIX Stock News Headlines

New law could create $3.7 trillion tsunami.
During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’s Project MAFA,” and it could soon return America to a “new” gold standard. The Trump administration, Wall Street, and Silicon Valley are all pushing it forward. The President himself calls the plan “incredible.” Already, it’s helping small plays jump as high as 300%, 318%, 520%, and even 600%.tc pixel
See More Headlines

EPIX Stock Analysis - Frequently Asked Questions

ESSA Pharma's stock was trading at $1.79 at the beginning of the year. Since then, EPIX shares have increased by 6.7% and is now trading at $1.91.

ESSA Pharma Inc. (NASDAQ:EPIX) announced its quarterly earnings data on Wednesday, August, 13th. The company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.17) by $0.08.

ESSA Pharma's top institutional shareholders include Bank of America Corp DE (1.41%), DLD Asset Management LP (0.71%), BNP Paribas Financial Markets (0.61%) and LMR Partners LLP (0.45%). Insiders that own company stock include Bvf Partners L P/Il, David Ross Parkinson, Peter Virsik and Growth N V Biotech.
View institutional ownership trends
.

Shares of EPIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that ESSA Pharma investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), Jabil (JBL), Builders FirstSource (BLDR) and CymaBay Therapeutics (CBAY).

Company Calendar

Last Earnings
8/13/2025
Today
8/19/2025
Record date for 8/22 Dividend
8/19/2025
Dividend Payable
8/22/2025
Ex-Dividend for 8/22 Dividend
8/25/2025
Fiscal Year End
9/30/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:EPIX
CIK
1633932
Employees
50
Year Founded
2009

Price Target and Rating

High Price Target
$2.00
Low Price Target
$2.00
Potential Upside/Downside
+4.7%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.56)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$28.54 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-21.71%
Return on Assets
-21.22%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
69.06
Quick Ratio
69.06

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.30 per share
Price / Book
0.83

Miscellaneous

Outstanding Shares
47,310,000
Free Float
39,975,000
Market Cap
$90.36 million
Optionable
Optionable
Beta
1.55

Social Links

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:EPIX) was last updated on 8/20/2025 by MarketBeat.com Staff
From Our Partners